Our mission is to enable Cell & Gene Therapies to deliver population-level health outcomes, realizing the extraordinary potential of humanity’s most powerful therapeutic modality – our cells, augmented. We contribute intelligent production systems for the manufacture of Cell & Gene Therapies.

Industry representative to the Centre for the Commercialisation of Regenerative Medicine

The brain-world interface is a new frontier for disruptive healthtech, and Neo-Bionica is at the cutting edge of neuromonitoring and neuromodulation devices. I structure collaboration deals that accelerate path to market for some of the world's most exciting neurotech companies by aligning with and leveraging Neo-Bionica's capabilities.

I drive industrialisation of advanced biologics - cell, gene and tissue therapies - for companies developing game-changing therapeutics.

CH4Global aims to meaningfully impact anthropogenic climate change, eliminating methane emissions from ruminant livestock through the dietary inclusion of the red algae Asparagopsis, cultivated, farmed and processed within our supply chain.Nascent industries poised for rapid growth need strong foundations. I led the design, build and commissioning of CH4's initial land-based grow-out and processing facility in South Australia. As the R&D team developed their in-depth knowledge of cultivation and processing conditions, I structured the foundations for a massively scalable production, conversion and delivery model for Asparagopsis-derived stockfeeds to meet ambitious global expansion timeline, cost-of-goods, and consistent product quality objectives. Together with the Australian GM. I helped secure a critical $3.8m grant from Australia's Federal Securing Raw Materials Program, to support scaling our South Australian operations for serious impact.

I met the founders of CH4 Global in 2019 and knew I had to help. Climate change is an existential challenge. CH4 Global was poised to massively contribute via the elimination of methane emissions from livestock, at the same time improving the health of the livestock, benefiting terrestrial and marine farmers and the environments they manage, and building a positive new global industry.Within the Advisory Board, I assessed commercial and operational market opportunities, mapped R&D pathways, established commercial relationships with University, Government and Private entities, and supported capital raising and team building to empower CH4 Global's trajectory.

Invetech's Cell Therapy business unit delivers bespoke commercial-scale automated manufacturing solutions for cell, gene and tissue therapies.I stepped into the leadership of Invetech's Cell Therapy group at a difficult time for the nascent Cell Therapy industry - efficacies were promising but variable, business models were unclear, and a number of landmark clinical trials had suffered serious adverse events. FDA approval of Novartis' Kymriah ushered in a new era, and the industry could begin appreciating the manufacturing and commercial viability challenge Cell & Gene Therapies present. Over 4 years I grew the business at CAGR >100%, evolving the strategic business focus, emphasising attentiveness to the voice of the customer, building a superpower global team and the systems/processes to let them soar, and establishing a strong market presence. It's an honour to have worked with the majority of global biopharma's, and played a role in the manufacture of the majority of Cell & Gene Therapies available today. Equally exiting was the opportunity to drive manufacturing excellence for some of the world's most dynamic and innovative pre-clinical groups across cell, gene and tissue therapies - many of these will change the world for patients in need.I couldn't be more proud of my global team - a diverse and dynamic group of extraordinary individuals with a singular passion for bringing next-generation therapies to patients in need through advanced manufacturing. On behalf of my team, I was honoured to accept a medal for innovation at Fortive’s 2019 Growth & Innovation Conference, followed by a prestigious Australian Good Design Award Gold Accolade in the Product Design, Medical and Scientific category in recognition for outstanding design and innovation.

I re-joined Invetech to lead a multi-stream global development program for one of the world's most advanced oncology therapeutic candidates. At the program's peak, I had 7x internal teams coordinating over 80 brilliant scientists and engineers. That combined with a huge pool of talent at our Client, as well as the development and integration of critical 3rd party collaborating entities. Ultimately, the therapy didn't meet its Phase III endpoints and was wound back. Yet the manufacturing maturity was a paradigm shift in the industry, with many assets remaining in circulation, and many of the concepts now industry standard.Following that, I established and managed numerous development programs for clients in North America, Europe, the UK, Japan, Korea and Australia.

Invetech is an inaugural member of the Fortive group of companies, within the Healthcare portfolio.

Industry representative to Australia's Federal Cooperative Research Centre for Cell Therapy Manufacturing.

Deakin's C-MMR performs world-class medical research that focuses on the molecular basis of health and disease. Research areas include cancer, molecular bioscience, metabolic and musculoskeletal medicine, infection and immunity. The C-MMR aims to translate research findings into novel strategies for optimising health and developing new therapeutics and diagnostics. C-MMR was supported by Brandon BioCatalyst.

Danaher acquired Invetech in October 2006 as part of the Vision Systems acquisition.

McKinsey & Company is the trusted advisor and counsellor to many of the world's most influential businesses and institutions.I supported clients in developing strategic direction and operational excellence across industries including banking & finance, PE/VC, minerals & mining, primary industry, healthcare, defence and large retail.

I was lucky enough to support the full-time, part-time and executive MBA cohorts as a tutor across Economics and Finance streams, supporting the teaching of Sven Feldmann and Sam Wylie respectively - two absolute giants in their domain.

I delivered an 'Economics for Science Graduates' course on behalf of Melbourne University's Faculty of Science, to assist our best and brightest minds with navigation of financial markets, the funding environment, and ultimately research translation.

Invetech's Manufacturing Innovation group evolved from custom automation for high-tech manufacturing (everything from medical device consumables to supercapacitors) into a dedicated life-science focused group that would ultimately be re-badged the Cell Therapy group.I delivered a series of incredible projects on behalf of clients around the world, with my focus exclusively on Cell and Gene Therapy manufacturing systems.

I led Mechanical and Systems teams across a diverse pool of projects for global Cell & Gene Therapy clients.

My dream job - I developed next-generation manufacturing technologies for Cell, Gene and Tissue therapies, as well as Medical Diagnostic Instruments. Brilliant clients, ambitious programs, dynamic teams!

Danaher acquired Invetech in October 2006 as part of the Vision Systems acquisition.